Wyss Geneva Steps Into Its Next Chapter
The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients.
Wyss Center Partners with BrainScape Medical to License Groundbreaking Epios® Technology
The Wyss Center for Bio and Neuro Engineering is pleased to announce a strategic partnership with BrainScape Medical, a newly established company specializing in long-term brain monitoring and neurostimulation. This collaboration marks a major step in translating innovative neurotechnology into real-world clinical solutions.
Wyss Center Appoints Dr. Craig Cook as New Head of Business Development and Licensing
The Wyss Center, a leading non-profit research center dedicated to innovating and accelerating technologies and therapies for neurological and mental health disorders, is pleased to announce the appointment of Craig Cook, MD, MBA, to the leadership team as Head of Business Development and Licensing. Dr. Cook brings more than 25 years of impressive executive leadership and entrepreneurial expertise in the fields of biotech, medtech and clinical medicine.
Wyss Center Geneva Appoints Erwin Böttinger as new Chief Executive Officer
The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Prof. Dr. med. Erwin Böttinger as its new Chief Executive Officer (CEO).
GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease
GliaPharm SA, a biotech company that specializes in the research and development of novel therapies to treat and prevent neurological diseases, and the Wyss Center, a non-profit organization dedicated to accelerating discoveries in neuroscience to improve patient lives, today announced a collaboration to develop new treatments for Alzheimer's disease.
Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud
The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and review of neural signals, including the ultra-long-term data recorded by an emerging generation of devices for remote brain monitoring. Its novel features allow seamless navigation of datasets covering months and years while access through a web browser allows clinicians to access patient data anywhere and anytime.
Wyss Center Partners With Artiria Medical to Accelerate a Novel Therapy for Cerebral Vasospasm
The Wyss Center and Artiria Medical today announced a new partnership to accelerate the translation of a novel technology that has the potential to reduce deaths and improve quality of life for stroke patients. Artiria Medical, an early-stage medical device company focused on disruptive neurovascular products, has been developing the technology and is now joining forces with the Wyss Center, a non-profit organization dedicated to bringing state-of-the-art therapies to the patient. The team has received support from the Swiss Innovation Agency, Innosuisse, to test and validate the efficacy of the therapy preclinically, in preparation for human clinical studies.
